iBio Reports New Material Agreement & Financial Obligation

Ticker: IBIO · Form: 8-K · Filed: 2024-01-19T00:00:00.000Z

Sentiment: neutral

Topics: debt, agreement, financial-obligation

TL;DR

**iBio just took on a new financial obligation, watch for details on what it is.**

AI Summary

iBio, Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 16, 2024, related to entering a material definitive agreement and creating a direct financial obligation. This filing indicates a significant new commitment or debt for the company, which could impact its financial health and future operations. For investors, this matters because new financial obligations can affect profitability, cash flow, and ultimately, the stock's value, depending on the terms and purpose of the agreement.

Why It Matters

This filing signals a new financial commitment for iBio, Inc., which could either fuel growth or strain resources, directly impacting shareholder value.

Risk Assessment

Risk Level: medium — The filing indicates a new financial obligation without disclosing specific terms, creating uncertainty about its potential impact on the company's financial health.

Analyst Insight

A smart investor would await further details on the nature and terms of the 'Material Definitive Agreement' and 'Direct Financial Obligation' to assess their potential impact on iBio's financial health and future prospects before making any investment decisions.

Key Players & Entities

Forward-Looking Statements

FAQ

What was the specific date of the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 16, 2024.

What are the two main items of information reported in this 8-K filing by iBio, Inc.?

The two main items of information reported are "Entry into a Material Definitive Agreement" and "Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant."

What is iBio, Inc.'s Commission File Number as stated in the filing?

iBio, Inc.'s Commission File Number is 001-35023.

Where is iBio, Inc.'s principal executive office located according to the filing?

iBio, Inc.'s principal executive office is located at 8800 HSC Parkway, Bryan, Texas 77807.

What is the par value per share of iBio, Inc.'s Common Stock?

The par value per share of iBio, Inc.'s Common Stock is $0.001.

Filing Stats: 1,192 words · 5 min read · ~4 pages · Grade level 13 · Accepted 2024-01-19 16:36:09

Key Financial Figures

Filing Documents

01. Entry Into a Material Definitive Agreement

Item 1.01. Entry Into a Material Definitive Agreement. Credit and Security Agreement On January 16, 2024, iBio, Inc. (the "Company"), entered into a credit and security agreement (the "Credit and Security Agreement") with Loeb Term Solutions LLC, an Illinois limited liability company ("Lender"), for a term loan or equipment line of credit loan (the "Loan") pursuant to which the Company issued to Lender a term promissory note in the principal amount of $1,071,572 (the "Term Note") bearing interest at the Prime Rate, as quoted in the Wall Street Journal plus 8.5% (the "Effective Rate"), for proceeds of $1,027,455.23 after payment of $42,862.88 to Lender as an origination fee, $1,172.89 for appraisal costs, and $75.00 for bank wire fees. The Term Note provides for monthly payments of principal and interest based on a four-year amortization period, with a balloon payment of all principal, accrued interest and any other amounts due on the two year anniversary of the Term Note. The Credit and Security Agreement granted to Lender a security interest in substantially all of the Company's assets other than any intellectual property related to any of the Company's filed patents (the "Collateral") to secure the Company's obligations under the Term Note. The Term Note is subject to a prepayment fee of: 4% of the principal amount being prepaid if the Term Note is prepaid during the first 12 months from its issuance, and 3% of the principal amount being prepaid if the Term Note is prepaid during the second 12 months from its issuance date. The Credit and Security Agreement provides that the Company may request that Lender make further loan advances to the Company subject to certain conditions, including that the Company is not otherwise in default under the Credit and Security Agreement and its obligations and liabilities to Lender do not exceed a borrowing base equal to the lesser of: (a) eighty percent (80.0%) of the forced liquidation value of the Company's Eligible Equ

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Credit and Security Agreement, dated January 16, 2024, by and between iBio, Inc. and Loeb Term Solutions LLC 10.2 Schedule to Credit and Security Agreement, dated January 16, 2024, by and between iBio, Inc. and Loeb Term Solutions LLC 10.3 Term Promissory Note, dated January 16, 2024, in the principal amount of $1,071,572 10.4 Validity Guarantee, dated January 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 19, 2024 IBIO, INC. By: /s/ Marc A. Banjak Name: Marc A. Banjak Title: General Counsel and Corporate Secretary

View on Read The Filing